AFFILIATIONS
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 University of Pennsylvania, Philadelphia, Pennsylvania, United States
17 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
18 University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction: BCMA-directed CAR T-cell therapy (CART) results in profound cytopenias, B-cell depletion, and hypogammaglobulinemia. Understanding the effects of lymphodepletion (LD) and BCMA CART on immune reconstitution in relapsed/refractory multiple myeloma (RRMM) patients (pts) is critical to risk stratification and defining potential therapeutic approaches.
Methods: We performed a retrospective single-center analysis of 207 RRMM pts treated with cilta-cel (n=133, median follow-up 25.2 months (mo)) or ide-cel (n=74, median follow-up 42.3 mo) from 6/2021-2/2025. Patients were censored at the time of maintenance initiation and/or progression (data cutoff: 7/2026). We characterized cellular and humoral immune recovery and their association with clinical outcomes using Kaplan-Meier and univariate/multivariate analyses.
Results: Pts were heavily pretreated (72.5% triple-class refractory, 17.4% prior BCMA therapy exposure). Median progression-free survival (PFS) was longer in cilta-cel than ide-cel (27.7 vs 9.9 mo, p<0.001). CART-associated immune-related adverse events (CirAE) were more prevalent in cilta-cel pts (20.3% vs 4.1%, p<0.01). Pre-LD cytopenias (109 cells/L) were common (median absolute lymphocyte count (ALC) 0.5, median absolute neutrophil count (ANC) 2.7). However, most pts (73%) had low (0-1) CAR-HEMATOTOX (HT) scores; high-risk scores (>1) were more common in ide-cel recipients (45% vs 17%, p<0.01) who were more heavily pre-treated. LD worsened lymphopenia (median ALC 0.01) and neutropenia (median ANC 1.2). Ide-cel treated pts experienced earlier ANC nadirs (6 vs 8 days, p<0.001). Most pts experienced cell count recovery (ANC>1, ALC>0.5) by one month (M1). Complete count recovery was more common following cilta-cel (p=0.03) and was associated with lower HT scores (p<0.001) and fewer prior lines of therapy (p=0.02). Pre-LD T-cell counts (cells/µL) were lower in ide-cel pts (CD3 443 vs 542; p=0.03, CD4 173 vs 263; p=0.004, CD8 195.5 vs 241; p=0.09). CD4 and CD8 T-cell nadirs occurred at day 7 with median CD4 and CD8 recovery (>150) achieved by M6 and M3 respectively. Higher peak lymphocyte count within the first 14 days (seen in cilta-cel pts) was associated with increased likelihood of CRS and CirAE (p<0.01). Profound CD4 lymphopenia (<50) at M1 was associated with reduced PFS (3.3 vs 24.4 mo, p<0.001). T-cell counts remained below baseline at 1 year (CD4 184, CD8 129; p=0.49). Prolonged B-cell aplasia was common with median B-cell counts at 14/µL by one year. We used IgM as a proxy for humoral recovery given prevalent use of IVIG. Most pts (95.6%) had undetectable IgM levels shortly after CART with more than half (53.6%) achieving IgM detectability. Ide-cel treated pts had higher rate of IgM detectability over time (sHR 2.2, 95% CI 1.5-3.2, p<0.001) with earlier median time to IgM detectability (6.4 vs 21.3 mo). Evidence of humoral recovery was accompanied by the appearance of non-M-spike immunoglobulin bands in 20% of evaluable pts at M6. Pts with IgM detectability at M3 were at increased risk for progression (HR 2.7, 95% CI 1.5-4.9, p=0.002). Although most pts (86.5%) experienced prolonged undetectable or low serum free light chains (SFLC), 27% had evidence of SFLC normalization with delayed time to normalization in cilta-cel pts (26.7 vs 13.5 mo). CART product, prior bispecific and BCMA exposure, and sex were associated with IgM detectability (overall model p<0.001). By M6, 60.9% of pts developed infections, resulting in hospitalizations in 42.9% and death in 6.3% with no difference by CART product. Viral infections predominated, while invasive fungal infections were rare (2.4%). Pts with higher HT scores, unrecovered ALC, and CirAE (all p<0.02) were at higher risk for infections resulting in hospitalizations. Pts receiving IVIG (80.7% of pts) despite persistent immunoparesis experienced infection rates comparable to those with immune reconstitution.
Conclusion: These findings highlight significant cellular and humoral immune dysfunction after BCMA CART. Early lymphopenia and rapid IgM recovery were associated with inferior PFS, serving as predictive biomarkers and opportunities for early intervention. Cilta-cel resulted in delayed but greater lymphocyte expansion, likely contributing to higher likelihood of toxicities and sustained immunoparesis. Despite this, pts treated with cilta-cel were not more vulnerable to infections with demonstrated efficacy of IVIG in mitigating infection-related morbidity.
DISCLOSURES
Heta Patel, MD: No relevant conflicts of interest to declare.